Strategies for the production of soluble interferon-alpha consensus and potential application in arboviruses and SARS-CoV-2

Full metadata record
DC FieldValueLanguage
dc.contributorLab. Desenvolvimento de Vacinaspt_BR
dc.contributor(LMP) Laboratório Multipropósitopt_BR
dc.contributorLab. Virologiapt_BR
dc.contributor(LABV) Laboratório de Biotecnologia Viralpt_BR
dc.contributor.authorGrabarz, Felipept_BR
dc.contributor.authorLopes, Alexandre Paulo Yaguept_BR
dc.contributor.authorBarbosa, Flávia Ferreirapt_BR
dc.contributor.authorBarazzone, Giovana Cappiopt_BR
dc.contributor.authorSantos, Jademilson Celestino dospt_BR
dc.contributor.authorBotosso, Viviane Fongaropt_BR
dc.contributor.authorJorge, Soraia Attie Calilpt_BR
dc.contributor.authorNascimento, Ana Lúcia Tabet Oller dopt_BR
dc.contributor.authorAstray, Renato Mancinipt_BR
dc.contributor.authorGonçalves, Viviane Maimonipt_BR
dc.identifier.citationGrabarz F, Lopes APY, Barbosa FF, Barazzone GC, Santos JC, Botosso VF, et al. Strategies for the production of soluble interferon-alpha consensus and potential application in arboviruses and SARS-CoV-2. Life. 2021 May;11(6):460. doi:10.3390/life11060460.pt_BR
dc.description.abstractBiopharmaceutical production is currently a multibillion-dollar industry with high growth perspectives. The research and development of biologically sourced pharmaceuticals are extremely important and a reality in our current healthcare system. Interferon alpha consensus (cIFN) is a non-natural synthetic antiviral molecule that comprises all the most prevalent amino acids of IFN-α into one consensus protein sequence. For clinical use, cIFN is produced in E. coli in the form of inclusion bodies. Here, we describe the use of two solubility tags (Fh8 and DsbC) to improve soluble cIFN production. Furthermore, we analyzed cIFN production in different culture media and temperatures in order to improve biopharmaceutical production. Our results demonstrate that Fh8-cIFN yield was improved when bacteria were cultivated in autoinduction culture medium at 30 °C. After hydrolysis, the recovery of soluble untagged cIFN was 58% from purified Fh8-cIFN molecule, fourfold higher when compared to cIFN recovered from the DsbC-cIFN, which achieved 14% recovery. The biological activity of cIFN was tested on in vitro model of antiviral effect against Zika, Mayaro, Chikungunya and SARS-CoV-2 virus infection in susceptible VERO cells. We show, for the first time, that cIFN has a potent activity against these viruses, being very low amounts of the molecule sufficient to inhibit virus multiplication. Thus, this molecule could be used in a clinical approach to treat Arboviruses and SARS-CoV-2.pt_BR
dc.description.sponsorship(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.rightsOpen accesspt_BR
dc.titleStrategies for the production of soluble interferon-alpha consensus and potential application in arboviruses and SARS-CoV-2pt_BR
dc.rights.licenseCC BYpt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.subject.keywordsolubility tagpt_BR
dc.identifier.citationabntv. 11, n. 6, 460, maio. 2021pt_BR
dc.identifier.citationvancouver2021 May;11(6):460pt_BR
dc.contributor.butantanGrabarz, Felipe|:Aluno|:Laboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanLopes, Alexandre Paulo Yague|:Pesquisador|:Laboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanBarbosa, Flávia Ferreira|:Técnico|:Laboratório Multipropósito Viralpt_BR
dc.contributor.butantanBarazzone, Giovana Cappio|:Pesquisador|:Laboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanSantos, Jademilson Celestino dos|:Aluno|:Laboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanBotosso, Viviane Fongaro|:Pesquisador|:Lab. Virologiapt_BR
dc.contributor.butantanJorge, Soraia Attie Calil|:Pesquisador|:Laboratório de Biotecnologia Viralpt_BR
dc.contributor.butantanNascimento, Ana Lúcia Tabet Oller do|:Pesquisador|:Laboratório de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanAstray, Renato Mancini|:Pesquisador|:Laboratório Multipropósito Viralpt_BR
dc.contributor.butantanGonçalves, Viviane Maimoni|:Pesquisador|:Laboratório de Desenvolvimento de Vacinas|:Autor de correspondênciapt_BR
dc.sponsorship.butantan(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2014/50981-0pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2016/50413-8pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦88882.377102/2019-01pt_BR
dc.sponsorship.butantanFundação Butantan¦¦pt_BR
item.fulltextCom Texto completo-
Appears in Collections:Artigos de periódicos

Files in This Item:

Size: 47.99 MB
Format: Adobe PDF
Show simple item record

This item is licensed under a Creative Commons License Creative Commons